ClinicalTrialsDaily
Jan 27, 1:54 AM
$CRVS Clinical Deep Dive: Phase 1b AD data confirms ITK inhibition works.
> 75% EASI-75 at Wk 8 (Rivals 30mg Rinvoq)
> Clean safety (No JAK tox, No MACE)
> Treg expansion = Potential for disease modification.
Verdict: If Ph2 replicates, this is the Oral SOC killer.
$SNY $LEO.
Read more: www.clinicaltrialsdaily.com/soquelitinib-cpi-818-itk-inhibitor-results/
1 replies